Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus HN001 + Lactobacillus paracasei Lpc-37 + Bifidobacterium animalis ssp. Lactis HN019
- Development stage
- Unknown
- Lead developer
- International Flavors & Fragrances
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This multi-strain probiotic formula is a live biotherapeutic product consisting of three specific bacterial strains: *Lactobacillus rhamnosus* HN001, *Lactobacillus paracasei* Lpc-37, and *Bifidobacterium animalis ssp. Lactis* HN019. It is currently being evaluated by the University of São Paulo in a Phase 4 clinical trial (NCT03021161) for the prevention of occupational allergic sensitization and asthma in laboratory animal workers and students exposed to small rodents. The intervention is administered orally in capsule form at a dose of 10^9 CFU once daily. The formula aims to modulate the gut-lung axis and immune response to reduce bronchial hyperresponsiveness and respiratory symptoms in high-risk populations.
- Other names
- Probiotic FormulaMulti-strain probiotic formula
Beyond the preview
Go deeper on Lactobacillus rhamnosus HN001 + Lactobacillus paracasei Lpc-37 + Bifidobacterium animalis ssp. Lactis HN019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus HN001 + Lactobacillus paracasei Lpc-37 + Bifidobacterium animalis ssp. Lactis HN019.